Do checkpoint inhibitors carry endocrine dysfunction risk?

Immune-related adverse events, including pneumonitis, are not more common in patients with metastatic lung cancer who receive both immune checkpoint inhibitors and thoracic radiotherapy, according to a research letter published online September 28 in JAMA Oncology.
MPR